VEGFA and neoplasm: Bevacizumab, as a recombinant human monoclonal antibody against vascular endothelial growth factor (VEGF), has been proven to specifically bind to VEGF and block its binding to receptors, not only affecting the generation of new blood vessels but also leading to the degeneration of existing blood vessels, thereby further inhibiting tumor growth.